An Early Phase 1 interventional study of Drug A (Blinded Drug) and Drug B (Blinded Drug) in Opioid Use Disorder and Opioid Dependence, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by University of Maryland, Baltimore · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore — 6 open to participants now, 8 under way, 2 of them phase 3. Opioid-Related Disorders · University of Maryland, Baltimore.
Among the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 10th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →6 of the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore are open now, in 1 country. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–75
University of Maryland, Baltimore · Sites in United States
Ages 18–65
University of Maryland, Baltimore · Sites in United States
Ages 18–100
University of Maryland, Baltimore · Sites in United States
Ages 18–75
University of Maryland, Baltimore · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2
First in 2017; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 50 across the 15 interventional studies, 30 across the 1 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
5 of the studies in Opioid-Related Disorders by University of Maryland, Baltimore that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT05027919University of Maryland, BaltimoreAssessing a Clinically-meaningful Opioid Withdrawal Phenotype | 2027-01-30 |
| NCT05511909University of Maryland, BaltimoreEvaluating Buspirone to Treat Opioid Withdrawal | 2027-01-31 |
| NCT07128524University of Maryland, BaltimoreKetones for Opioid Craving | 2027-08-31 |
| NCT07094672University of Maryland, BaltimoreDevelopment of an Opioid Withdrawal Clinical Outcome Assessment | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs. Suvorexant is not approved as a treatment to reduce drug use but is approved by the Food and Drug Administration (FDA) to treat insomnia (trouble falling asleep or staying asleep). This study consists of a screening visit and an approximate 14 to 16 day inpatient (overnight) stay at the University of Maryland, Baltimore. Participants will be stabilized on hydromorphone, randomly assigned to receive either suvorexant or placebo, and complete 5 experimental sessions that include taking blinded study medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double blind administration of suvorexant once per day during residential stay until discharge
Drug: Drug A (Blinded Drug) · Drug: Drug B (Blinded Drug) · Drug: Drug C (Blinded Drug) · Drug: Drug D (Blinded Drug) · Drug: Suvorexant (20mg/day)
Double blind administration of placebo once per day during residential stay until discharge
Drug: Drug A (Blinded Drug) · Drug: Drug B (Blinded Drug) · Drug: Drug C (Blinded Drug) · Drug: Drug D (Blinded Drug) · Drug: Placebo
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Drug page: SuvorexantStudies of SuvorexantSuvorexant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Double blind administration of suvorexant once per day during residential stay until discharge.
Double blind administration of placebo once per day during residential stay until discharge.
Demand Intensity
Consumption of blinded drug at unconstrained price as measured by an incentivized demand task. Minimum value is 0, maximum value is not constrained. Higher scores indicate more drug consumption at unconstrained price (a worse outcome).
Time frame: Upon completion of experimental session (~8 hours post drug administration)
Demand Elasticity
Changes in blinded drug consumption with changes in price as measured by an incentivized demand task. There is no minimum or maximum value. Higher scores indicate greater drug price sensitivity (a better outcome).
Time frame: Upon completion of experimental session (~8 hours post drug administration)
Cross-Price Elasticity
Change in consumption of price-fixed good based on change in price of price varying good. Positive values indicate a substitute, negative values indicate a complement, and zero values indicate an independent commodity.
Time frame: After Experimental Session 4
Total Mean Sleep Time
Mean total number of minutes slept per night as measured by actigraphy and self-reported sleep diary. Mean total sleep time will be collected daily.
Time frame: Through study completion, up to two weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Jan 2028, 52 months after the start.
Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 52 months is above that.
Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Maryland, Baltimore →